Consensus minimum hemoglobin level above which patients with myelodysplastic syndromes can safely forgo transfusions

Abstract

The anemia of MDS often results in decreased quality of life, which is invoked to justify red cell transfusions; however, there are sparse data regarding the minimum hemoglobin (Hb) at which it is safe to forgo transfusions for patients with no evidence of end-organ damage. This issue is even more important in the COVID-19 era, where decreases in blood donations have stressed the blood supply. In March 2018, using a modified Delphi method, we convened a panel of 13 expert MDS clinicians for three iterative rounds to discuss a minimum safe Hb for this population. While the panel was unable to reach the pre-set consensus of 75% for a specific Hb threshold, there was 100% consensus that it be no greater than 7.5 g/dL. Our data suggest that, given no end-organ effects of anemia, patients with MDS can safely forgo transfusions with a Hb of 7.5 g/dL or higher.

Keywords:

• Myelodysplastic syndromes
• transfusion
• hemoglobin threshold

Disclosure statement

No authors have any relevant COI to report.

Additional information

Funding

This work was supported by a grant from the Dresner Foundation Myelodysplastic Syndrome (MDS) Research Fund.